Clinical efficacy and safety of umbralisib, a dual PI3Kδ/CK1-ϵ inhibitor, in treatment of hematologic malignancies

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-01-06
DOI
https://doi.org/10.3389/fonc.2025.1591759
Primary Topic
PI3K/AKT/mTOR signaling in cancer
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical efficacy and safety of umbralisib, a dual PI3Kδ/CK1-ϵ inhibitor, in treatment of hematologic malignancies

Y. Liu, Junmei Wang, Yanli Sun, Jingning Yang et al.
Frontiers in Oncology
PI3K/AKT/mTOR signaling in cancer
article

Clinical efficacy and safety of umbralisib, a dual PI3Kδ/CK1-ϵ inhibitor, in treatment of hematologic malignancies

Y. Liu, Junmei Wang, Yanli Sun, Jingning Yang, Hai-en Cheng, Yuying Zhao, Yanhua Sun, Yunke Zang
article en

Abstract

No abstract available for this paper.
Frontiers in OncologyVol. 15
Weifang Medical University (CN), Weifang People's Hospital (CN)
National Natural Science Foundation of China, Natural Science Foundation of Shandong Province
Good health and well-being
Openalex Percentile: Top 95%
PI3K/AKT/mTOR signaling in cancer
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.